BASKING RIDGE, N.J., Nov. 7, 2006 (PRIMEZONE) -- Millennium Biotechnologies (OTCBB:MBTG), manufacturer of Resurgex, a popular line of nutritional supplements, announced the appointment of Don Sperling, former Senior Vice President of NBA Entertainment to the Company's sports marketing team.
The Resurgex line had primarily been used to relieve fatigue commonly found in those with deficiencies of the immune system. In 2005, Millennium Biotechnologies began supplying professional sporting organizations with Resurgex to increase recovery and to improve performance in athletes undergoing rigorous training. The appointment of Mr. Sperling is indication of the company's continuing focus on becoming one of the leading suppliers of specialized nutritional supplements to professional and collegiate athletes.
Mr. Sperling brings to Millennium Biotechnologies over 20 years of sports marketing and television media production experience. During Mr. Sperling's fifteen year tenure as Senior Vice President and Executive Producer of NBA Entertainment, NBA TV and NBA.com, the NBA became the largest producer and broadcaster of sports programming and digital media with over 240 affiliates worldwide.
"Don's background is perfectly suited to design targeted marketing strategies appropriate for the launch of our line of sports products," said Jerry Swon, President and CEO of Millennium Biotechnologies. "Don is the perfect leader to help us build off of our current success."
Not only was Don the creator of "NBA Inside Stuff," ABC's longest running weekly sports and entertainment show, but in 1997 he was one of the leading forces behind the launch of the Women's National Basketball Association (WNBA), earning Don and his team the coveted "Sports Marketer of the Year" award.
"This cutting edge product is in the right place at the right time," said Don Sperling. "Resurgex has clinically proven benefits that will help all athletes perform at peak levels longer and decrease recovery time from modern day training regimens."
About Millennium Biotechnologies, Inc.
Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(r), RESURGEX Plus(r), and RESURGEX Select(r), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions. In addition, Resurgex products were developed to address the multiple nutritional needs of professional athletes as well as those who are involved in regular exercise programs. Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTCBB:MBTG). For more information about Millennium Biotechnologies, please call Frank Guarino, Chief Financial Officer, at FGuarino@Milbiotech.com or call (908) 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com.
Millennium plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement which will contain information about Millennium, the sale of its assets and the formation and capitalization of RAC Nutrition (the "Proposed Transaction") and related matters. Stockholders are urged to read the proxy statement carefully when it is available, as it will contain important information that stockholders should consider before making a decision about the Proposed Transaction. In addition to receiving the proxy statement from Millennium by mail, stockholders also will be able to obtain the proxy statement, as well as other filings containing information about Millennium, without charge, from the Securities and Exchange Commission's website (http://www.sec.gov). This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Millennium. Millennium and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Millennium's stockholders with respect to the Proposed Transaction. Information regarding any interests that Millennium's executive officers and directors may have in the Proposed Transaction will be set forth in the proxy statement.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.